Breaking
Microsoft Achieves 10 Consecutive Quarters of Record Revenue Surpassing $92 Billion in Latest Quarter Too Big to Ignore! Scientist Discovered a Massive 20-inch Fungus National Pharmaceutical Pricing Authority Reduces Prices of 543 Cancer Drug Brands by Up to 90% from November 9 Over 41,000 US DHS Immigration Agents’ Personal Data Exposed in Major Security Breach Indian Railway: Charging Points on Indian Trains Will Be Powered Down at Night to Boost Passenger Safety Measures Microsoft Achieves 10 Consecutive Quarters of Record Revenue Surpassing $92 Billion in Latest Quarter Too Big to Ignore! Scientist Discovered a Massive 20-inch Fungus National Pharmaceutical Pricing Authority Reduces Prices of 543 Cancer Drug Brands by Up to 90% from November 9 Over 41,000 US DHS Immigration Agents’ Personal Data Exposed in Major Security Breach Indian Railway: Charging Points on Indian Trains Will Be Powered Down at Night to Boost Passenger Safety Measures
MinuteBrief logo
India

National Pharmaceutical Pricing Authority Reduces Prices of 543 Cancer Drug Brands by Up to 90% from November 9

National Pharmaceutical Pricing Authority cuts prices of 543 cancer drug brands by up to 90%, effective November 9, easing treatment costs.

Mahbeez Parbeen | | 1 min read

National Pharmaceutical Pricing Authority Reduces Prices of 543 Cancer Drug Brands by Up to 90% from November 9
AI Generated | Minutebrief Team

In This Story

In Brief

  1. NPPA reduces prices of 543 cancer drug brands from November 9.
  2. Price cuts help improve affordability of cancer treatment in India.
  3. Dr Reddy’s 100 mg azacitidine injection price drops from ₹6,337 to ₹1,495.04.
  4. Price slashes reach up to 90% on essential cancer medicines.

Price cuts take effect from November 9

The National Pharmaceutical Pricing Authority (NPPA) has announced a significant reduction in the prices of 543 cancer drug brands, effective from November 9. The move aims to make cancer treatment more affordable for patients across India by slashing prices by up to 90% for key medications. The NPPA’s decision follows its continual efforts to regulate and rationalize the pricing of life-saving medicines. These reductions come amid concerns over the financial burden cancer treatments impose on patients and their families.

These price cuts are expected to improve accessibility and affordability of cancer care, potentially increasing treatment adherence and outcomes for patients. Healthcare providers may also find it easier to source these critical medications at controlled, lower prices. The NPPA has not only targeted single drugs but also various brands and dosages, underscoring a comprehensive approach to drug price regulation in the oncology segment.



More from India